EPI N06

Drug Profile

EPI N06

Alternative Names: EPI-N06

Latest Information Update: 11 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator EpiPharm AG
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Malignant melanoma; Nevus

Most Recent Events

  • 11 Apr 2016 Phase-I/II development is ongoing in Switzerland
  • 07 Jan 2016 EPI N06 is available for licensing as of 07 Jan 2016. http://www.epipharm.ch/
  • 01 Jan 2014 Phase-I/II clinical trials in Malignant melanoma (Prevention) in Switzerland (Topical) prior to January 2014
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top